sotatercept news

All news on sotatercept (also known as sotatercept-csrk and WINREVAIR): plants, production capacities, investments and involved companies.

30 October 2025
Merck Announces Q3 2025 Financial Results
Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.
27 October 2025
Merck's WINREVAIR Approved by FDA for Expanded PAH Treatment
WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.
30 September 2025
Merck's WINREVAIR Reduces PAH Clinical Worsening Risk by 76% in Phase 3 Trial
WINREVAIR, when started within a year of PAH diagnosis, significantly lowers clinical worsening risk. Safety profile aligns with previous trials. Results shared at ERS 2025 and published in NEJM.

Who will be producing sotatercept in the future?

Find out with chemXplore Analytics